PLAC1 and Familial prostate cancer: Anti-PLAC1-ADC showed selective cytotoxicity against PLAC1-expressing prostate cancer cells and profoundly increased potency of cytotoxic drug payload suggesting PLAC1 as a highly promising therapeutic target for ADC-based cancer immunotherapy.